N/A Completed N=21 Randomized Double-blind Treatment

Effect of Azilsartan on Aldosterone in Postmenopausal Females

Hypertension

Source: ClinicalTrials.gov NCT01774591 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2017

Primary outcomePrimary: 24-hour BP (Systolic) — 113; 129 mmHg

Summary

The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.

Outcome Measures

Outcome	Result	p-value
PRIMARY 24-hour BP (Systolic)	113; 129	—
PRIMARY 24-hour BP (Diastolic)	75; 89	—
SECONDARY Difference in 24-hour Urine Aldosterone Change From Baseline	-47.3; -5.3	—

Eligibility Criteria

Inclusion Criteria

Female
Ages 45-70
Post-menopause: have not had a menstrual period for one year or more
Diagnosed with Stage 1 hypertension
Body Mass Index (BMI) greater than or equal to 28

Exclusion Criteria

Male
Diagnosed with Stage 2 hypertension
Stage 1 hypertension requiring more than one agent
Pregnancy or attempting pregnancy
Use of oral contraceptive pills
Use of hormone replacement therapy
Use of steroids
Stage 3 or greater kidney disease
Diabetes mellitus
untreated hypothyroidism or hyperthyroidism
primary hyperaldosteronism
Cushing's disease
obstructive sleep apnea
chronic illness, e.g. chronic liver disease
NYHA class III or greater heart failure
moderate to severe lung disease

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01774591). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.